PSI Advisors’s Esperion Therapeutics ESPR Stock Holding History

PSI Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35.3K	Buy	+11,172	New	+$31.3K	0.01%	151
2026 Q1	–	Sell	-22,344	Closed	-$82.7K	–	159
2025 Q4	$82.7K	Buy	22,344 +8,844	+66%	+$28.6K	0.02%	123
2025 Q3	$35.8K	Sell	13,500 -24,672	-65%	-$47.7K	0.01%	137
2025 Q2	$37.6K	Buy	38,172 +24,672	+183%	+$24.7K	0.02%	112
2025 Q1	$19.4K	Hold	13,500	–	–	0.01%	372
2024 Q4	$29.7K	Hold	13,500	–	–	0.01%	346
2024 Q3	$22.3K	Hold	13,500	–	–	0.01%	410
2024 Q2	$30K	Sell	13,500 -3,500	-21%	-$8.23K	0.01%	335
2024 Q1	$45.6K	Hold	17,000	–	–	0.02%	265
2023 Q4	$50.8K	Buy	17,000 +10,500	+162%	+$13.6K	0.02%	259
2023 Q3	$6.37K	Hold	6,500	–	–	﹤0.01%	559
2023 Q2	$9.04K	Hold	6,500	–	–	﹤0.01%	504
2023 Q1	$10.3K	Buy	+6,500	New	+$33.6K	0.01%	427

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

PSI Advisors's ESPR Position: Q2 2026 in Review

PSI Advisors opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 11,172 shares worth $35.3K. The stake represents 0.01% of the portfolio and ranks #151 among its holdings. This is a return to the name: PSI Advisors previously reported a position in ESPR as recently as Q4 2025.

PSI Advisors first reported a position in ESPR in Q1 2023 and has held it in 13 quarters since. The position peaked at $82.7K in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

PSI Advisors held 11,172 shares of Esperion Therapeutics worth $35.3K as of Q2 2026.
Esperion Therapeutics was a new PSI Advisors position in Q2 2026.
Esperion Therapeutics made up 0.01% of PSI Advisors's portfolio in Q2 2026, its #151 holding.
PSI Advisors first reported a position in Esperion Therapeutics in Q1 2023 and has held it in 13 quarters since.
PSI Advisors's Esperion Therapeutics position peaked at $82.7K in Q4 2025.
191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on PSI Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.